RESEARCHERS have launched a project which aims to unlock one of the biological keys that give rise to breast cancer.
Leading Glasgow researchers are studying how a molecule known to be associated with the development of blood cancer could also be involved in a particularly aggressive type of breast cancer.
The project will explore if this molecule could be used to develop a new treatment for the disease, potentially saving hundreds of lives.
More than 1,000 women in the Greater Glasgow and Clyde area are diagnosed with breast cancer each year on average, and more than 200 die from the disease.
Across the UK, 50,000 women are diagnosed with the disease each year, and 12,000 women still die from the disease every year.
The project, funded by a pilot grant of around £15,000 from research charity Breast Cancer Campaign, is being undertaken by Dr Karen Blyth, based at the Beatson Institute for Cancer Research in Glasgow, and co-investigator Dr Kirsteen Campbell.
The scientists plan to carry out experiments involving two molecules called 'MCL-1' and 'MYC', which are known to be involved in the development of cancer, and particularly in leukaemia.
Around 15 per cent of breast cancers are found to be 'triple-negative', a particularly aggressive form of the disease that cannot be treated with targeted drugs commonly used to treat other types of breast cancer.
Chemotherapy is also not effective for some patients, who are left with even fewer options.
Katherine Woods, senior research communications manager at Breast Cancer Campaign, said: "There are around 7,500 new cases of triple-negative breast cancer in the UK each year but no targeted treatment options.
"We must find more effective ways of treating these patients and innovative research from Drs Blyth and Campbell will help shed more light on how this type of the disease develops.
"This could eventually lead to the development of new treatments, improving patients' chances of survival."
Drs Blyth and Campbell will look at 500 samples of breast tumours donated by patients and test whether blocking MCL-1 could help improve treatments, using breast cancer cells grown in the lab and implanted into mice.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article